Presentation is loading. Please wait.

Presentation is loading. Please wait.

Volume 112, Pages (October 2017)

Published byBruce Blake Modified over 6 years ago

Similar presentations

Presentation on theme: "Volume 112, Pages (October 2017)"— Presentation transcript:

1 Volume 112, Pages 181-187 (October 2017)
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer  Martin Reck, Luis Paz-Ares, Paolo Bidoli, Federico Cappuzzo, Shaker Dakhil, Denis Moro-Sibilot, Hossein Borghaei, Melissa Johnson, Robert Jotte, Nathan A. Pennell, Frances A. Shepherd, Anne Tsao, Michael Thomas, Gebra Cuyun Carter, Faye Chan-Diehl, Ekaterine Alexandris, Pablo Lee, Annamaria Zimmermann, Andreas Sashegyi, Maurice Pérol  Lung Cancer  Volume 112, Pages (October 2017) DOI: /j.lungcan Copyright © 2017 The Authors Terms and Conditions

2 Fig. 1 Overall survival (A) and progression-free survival (B) in REVEL refractory patients (best response of progressive disease to first-line therapy) receiving ramucirumab and docetaxel compared with that in patients receiving placebo and docetaxel. CI, confidence interval; DOC, docetaxel; HR, hazard ratio; N, number of patients in treatment arm; PBO, placebo; RAM, ramucirumab. Lung Cancer  , DOI: ( /j.lungcan ) Copyright © 2017 The Authors Terms and Conditions

3 Fig. 2 Time to deterioration for Lung Cancer Symptom Scale in REVEL refractory patients. Summary of time to deterioration in each Lung Cancer Symptom Scale item and summary scores. ASBI, average symptom burden index; CI, confidence interval; DOC, docetaxel; HR, hazard ratio; LCSS, Lung Cancer Symptom Scale; N, number of patients in treatment arm; PBO, placebo; RAM, ramucirumab. Lung Cancer  , DOI: ( /j.lungcan ) Copyright © 2017 The Authors Terms and Conditions

4 Lung Cancer 2017 112, 181-187DOI: (10.1016/j.lungcan.2017.07.038)
Copyright © 2017 The Authors Terms and Conditions

5 Lung Cancer 2017 112, 181-187DOI: (10.1016/j.lungcan.2017.07.038)
Copyright © 2017 The Authors Terms and Conditions

6 Lung Cancer 2017 112, 181-187DOI: (10.1016/j.lungcan.2017.07.038)
Copyright © 2017 The Authors Terms and Conditions

Download ppt "Volume 112, Pages (October 2017)"

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Volume 389, Issue 10072, Pages (March 2017)

Volume 389, Issue 10072, Pages (March 2017)
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.
Fig. 1 Kaplan–Meier curves of post-progression survival (PPS) in the docetaxel and best supportive care (BSC) groups. Median PPS was 5.4 months in the.

Fig. 1 Kaplan–Meier curves of post-progression survival (PPS) in the docetaxel and best supportive care (BSC) groups. Median PPS was 5.4 months in the.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis  Nathan M. Mollberg, DO,

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis  Nathan M. Mollberg, DO,
Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: A systematic review and meta-analysis  Thomas W. Lee, Michael.

Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: A systematic review and meta-analysis  Thomas W. Lee, Michael.
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,
Anxiety After Diagnosis Predicts Lung Cancer–Specific and Overall Survival in Patients With Stage III Non–Small Cell Lung Cancer: A Population-Based Cohort.

Anxiety After Diagnosis Predicts Lung Cancer–Specific and Overall Survival in Patients With Stage III Non–Small Cell Lung Cancer: A Population-Based Cohort.
Volume 70, Issue 4, Pages (October 2016)

Volume 70, Issue 4, Pages (October 2016)
Volume 49, Issue 5, Pages (May 2006)

Volume 49, Issue 5, Pages (May 2006)
Volume 74, Issue 4, Pages (October 2018)

Volume 74, Issue 4, Pages (October 2018)
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,
A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy 

Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy 
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Similar presentations

Ads by Google